Methods for decreasing proliferation and preventing or treating a neuroendocrine cancer using an N-methyl D-aspartate-associated (NMDA) glutamate receptor antagonists or binding agent, such as an antibody, antibody fragment or peptide aptamer specific for a NMDA glutamate receptor, are disclosed.